TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cutaneous abdominal tissue thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid profile (LDL, HDL and triglyceride concentrations)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inflammatory markers concentration (IL6, CRP, TNF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Body composition- body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body composition- muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum Norepinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Expression of genes regulating skeletal muscle metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: trough/peak ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of maternal Grade 3 or higher adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of infant death
Endpoint domain: Mortality/survival
Primary endpoint: Composite outcome of adverse pregnancy outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Lower Urinary Tract Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Visual Analog Scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the ethinylestradiol concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the levonorgestrel concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean concentrations of serum marker(s) of protein status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean concentrations of serum marker(s) of micronutrient status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean concentrations of serum marker(s) of cardiovascular status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduced signs and symptoms of Parkinson's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of home falls requiring emergency admission
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Achieve Sustained Virological Response at Follow-up Week 24 (SVR24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With an Adverse Event Leading to Discontinuation of Study Medication
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Rate of Consent to Study Participation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent Rate of Device Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent Rate of Device Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of Using the Wise Device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients acquiring intestinal colonization of ESBL-producing Enterobacteriaceae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Difference in PET scan results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical performance of dual-energy CT colonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: GMTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Treatment patients experiencing major device-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Treatment patients experiencing any major adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients successfully implanted with study device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of patients implanted with right to left interatrial flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Emerging Behaviors Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum Voluntary Isometric Contraction (MVIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Unilateral bridge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Side-lying hip abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Vasodilator Response (Forearm Blood Flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of germline pathogenic/likely pathogenic variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Epworth's sleepiness scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Feasibility of reducing total dose of cyclophosphamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phenotypic detection of virulence marker of Enterococci (Gelatinase activity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Phenotypic detection of virulence marker of Enterococci (hemolytic activity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibiotic sensitivity test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pain and function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Grip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: central venous catheter-associated bloodstream infection (CLABSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of neurological sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response rate of pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle damage assay using Myoglobin biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle damage assay using Troponin T biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in Surgical Scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adherence to the palliative care consultation intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in the peak blood alcohol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in alcohol subjective effects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the area under the curve for blood alcohol concentration (BAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the rate of alcohol elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in body energy stores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Events Per Person-year
Endpoint domain: Mortality/survival
Primary endpoint: Subjective assessment of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loes score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma VLCFA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of SARS-CoV2 virus (COVID-19) collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical concordance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fcMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Airway remodeling (distance from the reticular membrane to the smooth muscle)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: safety and effectiveness of JNJ-31001074
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operator radiation dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Did Not Experience a Flare
Endpoint domain: Adverse events/effects
Primary endpoint: Participant-reported levels of subjective sexual arousal
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physiological genital response in women with FSAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of AHI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Who Received NRL-1 (Valtoco)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Distant corrected near visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients experiencing adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Histologic resolution of CIN2/CIN3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of immune inhibitory macrophages (CD11B+, CD163+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Asymptomatic HSV-2 Genital Shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With an HIV Viral Load of <500 Copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Septic complication
Endpoint domain: Adverse events/effects
Primary endpoint: Liver metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: survival of puerperae under mechanical ventilation
Endpoint domain: Mortality/survival
Primary endpoint: Graft dysfunction episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need of home nursing services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intra-coronary occlusive ECG ST-segment elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HDL-cholesterol changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of probable/proven invasive aspergillosis
Endpoint domain: Adverse events/effects
Primary endpoint: Change in mitochondrial capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CV Death or Heart Failure Hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: serum IL-21
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Mammographic Breast Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Clinically Significant Deep Surgical Site Infection (SSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Preoperative Venham clinical anxiety rating scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative Venham clinical anxiety rating scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Preoperative evaluation of salivary cortisol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postoperative evaluation of salivary cortisol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pain Threshold Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical Jump Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Minimum residual disease CR (MRD CR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse event/serious adverse event incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Time To Reach The Maximum Plasma Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under The Plasma Concentration-time Curve Extrapolated To Infinity (AUC0-Inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nail Psoriasis Severity Index (NAPSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Stone free rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ktrans change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD8 positive T-cells change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in self efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Daily Cigarillo Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Nicotine Equivalents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Spontaneous Bacterial Peritonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Confirmed Objective Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With Clinical Benefit Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Oxygenation Index (OI) at 24 hours of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Flow Mediated Dilatation of the Popliteal Artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Seroresponse (Percent Seroconversion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Impulsive-Compulsive Disorders severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of the third period of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Loose/watery Stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: masticatory muscle surface EMG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absolute Change in Mean Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing TEAEs Related to Idelalisib
Endpoint domain: Adverse events/effects
Primary endpoint: DAT SPECT striatal specific binding ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving the PK/PD target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rho/ROCK Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: eNOS Expression/Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bowel Movement Within 3 Days of Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Aortic valve calcium volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inflammation and endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood markers (TNF-a, IL-6, adiponectin, hsCRP, endothelin 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of the mobilization reproductibility coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion (degree) reproductibility coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal angular speed (degree.sec-1) reproductibility coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GADD34 expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Misclassification rate for recurrent disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Misclassification rate for high grade or low grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of high density SCS mode selected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualitative GBS Culture Result
Endpoint domain: Adverse events/effects
Primary endpoint: Control of IGF-I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: penetration - aspiration score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: residue score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood concentrations of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Heart rate and heart activity on EKG machine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pre-Operative Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dietary behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Digit Span Forward WAIS-IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Corsi block tapping test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Trail Making Test, Part A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Rey Auditory Verbal Learning Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Digit Span Backward WAIS-IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Corsi block-tapping test reversed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Vitiligo extent score (VES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients screened positive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Language Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection at 30 POD
Endpoint domain: Adverse events/effects
Primary endpoint: aerobic threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite adverse outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of microbiologic concordance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rehospitalization due to recurrence of atrial fibrillation (AF)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: activity and toxicity of GEMVIN combination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: optimal dose of GEMETO, GEMCAR, and GEMCIS combinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: activity and toxicity of GEMETO, GEMCAR, and GEMCIS combinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the burden of KS lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: [18F]FDOPA Ki values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Frontal Oxyhemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Frontal Deoxyhemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Serum Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anatomical closure grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Mu Rhythm Learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of sugammadex assessed by Train of four (TOF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preferred Method of Drug Administration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change of viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of development of Acute Respiratory Distress Syndrome (ADRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of cases with bleeding grade 3-4
Endpoint domain: Adverse events/effects
Primary endpoint: Number of cases with pneumothorax at post-procedural x-ray of the thorax
Endpoint domain: Adverse events/effects